Send to

Choose Destination
Klin Monbl Augenheilkd. 2018 May;235(5):553-561. doi: 10.1055/a-0577-8006. Epub 2018 Apr 12.

[Therapeutic Concepts for Treatment of Patients with Non-infectious Uveitis Biologic Disease Modifying Antirheumatic Drugs].

[Article in German; Abstract available in German from the publisher]

Author information

Augenzentrum und Ophtha-Lab, St. Franziskus-Hospital, Münster.
Universitäts-Augenklinik, Charité, Campus Virchow-Klinik, Berlin.


in English, German

Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of various non-infectious uveitis entities. Currently, the TNF-α-inhibitor Adalimumab is the only in-label therapeutic option, whereas, all other bDMARDs need to be given as an off-label therapy. bDMARDs are indicated in diseases refractory to conventional synthetic DMARD therapy and/or systemic steroids, or in patients in whom treatment with those is not possible due to side effects. Therapeutic mechanisms currently employed are cytokine-specific (interferons, inhibition of TNF-α or of interleukin [IL]-1-, IL-6- or IL-17-signalling), inhibit T cell costimulation (CTLA-4 fusion protein), or act via depletion of B cells (anti-CD20). All bDMARDs need to be administered parenterally, and therapy is initiated by the treating internal specialist only after interdisciplinary coordination of all treating subspecialties and after exclusion of contraindications. Regular clinical and laboratory monitoring is mandatory for all patients while under bDMARD therapy.


Conflict of interest statement

KW: keine. UP: institutionell: BMBF, EU, DFG; nicht institutionell: AbbVie, Alcon, Allergan, Bausch and Lomb, Bayer, Novartis, Santen, Sanofi, Thea. AH: institutionell: BMBF, DFG; nicht institutionell: AbbVie, Alimera, Sciences, Allergan, MSD, Pfizer, Santen, Xoma.

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center